Skip to content

April 28, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Commercial
Novartis shares fall as Entresto sales weaken

Commercial

Novartis shares fall as Entresto sales weaken

Pharmaphorum

Novartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026.

Read full story

pharminent April 28, 2026 (Last updated: April 28, 2026)

Pharmaphorum

Novartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026.

Read full story

Post navigation

Previous: Seaport and Hemab target $180m IPOs as biotech listings accumulate

Next: GSK eyes October FDA verdict on chronic hep B drug

Related Stories

Commercial

Lilly falls on slower start for Foundayo versus Wegovy

pharminent April 27, 2026

Commercial

Daiichi Sankyo shares slip after delaying annual earnings report

pharminent April 24, 2026

Commercial

Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels

pharminent April 24, 2026

You May Have Missed

Clinical Data

Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3

pharminent April 28, 2026

Clinical Data

AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer

pharminent April 28, 2026

M&A / Deals

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

pharminent April 28, 2026

Regulatory

GSK eyes October FDA verdict on chronic hep B drug

pharminent April 28, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.